Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
ASKA Pharmaceutical Holdings Co., Ltd. ( (JP:4886) ) has issued an announcement.
ASKA Pharmaceutical Holdings reported consolidated net sales of ¥54.5 billion for the nine months ended December 31, 2025, up 9.1% year on year, but operating profit fell 10.6% to ¥4.9 billion and profit attributable to owners of parent declined 4.7% to ¥3.9 billion, resulting in lower earnings per share despite higher revenue. The company’s financial position remained solid, with total assets rising to ¥112.7 billion and an equity ratio of 61.0%, and it maintained its full-year forecast for FY2025, targeting a 10.7% increase in net sales to ¥71.0 billion and double-digit growth in operating and ordinary profit, while keeping its annual dividend forecast unchanged at ¥55 per share, signaling confidence in earnings resilience and shareholder returns amid profit margin pressure.
The most recent analyst rating on (JP:4886) stock is a Hold with a Yen2610.00 price target. To see the full list of analyst forecasts on ASKA Pharmaceutical Holdings Co., Ltd. stock, see the JP:4886 Stock Forecast page.
More about ASKA Pharmaceutical Holdings Co., Ltd.
ASKA Pharmaceutical Holdings Co., Ltd. is a Japan-based pharmaceutical company listed on the Tokyo Stock Exchange, operating under Japanese GAAP. The group develops, manufactures and sells prescription drugs, with a focus on women’s health, endocrine and metabolic diseases, and other specialty therapeutic areas in the domestic market, while also pursuing growth through business combinations and portfolio expansion.
Average Trading Volume: 89,816
Technical Sentiment Signal: Strong Buy
Current Market Cap: Yen66.48B
For a thorough assessment of 4886 stock, go to TipRanks’ Stock Analysis page.